Bilateral Choroidal Effusions With Acute Myopic Shift After Daratumumab

Daratumumab is a CD38-directed monoclonal antibody increasingly used in haematological malignancies. Infusion-related reactions are well recognised, but ocular adverse events are uncommon and may be under-recognised. We report a man in his 30s with relapsed T-cell lymphoblastic lymphoma/leukaemia following allogeneic stem cell transplantation who developed acute bilateral blurred vision within 24 hours of his first daratumumab infusion. The infusion was complicated by a hypersensitivity reaction requiring treatment with antihistamines and corticosteroids. Ophthalmic assessment demonstrated unaided visual acuity of 6/9 in the right eye and 6/15 in the left eye, bilateral myopic refractive changes, normal intraocular pressures, and deep, quiet anterior chambers. Optical coherence tomography was unremarkable, whilst B-scan ultrasonography demonstrated small bilateral superior choroidal effusions. Following discussion with the treating haematology team, the patient was managed conservatively with ophthalmic monitoring whilst daratumumab was continued. At two weeks, his visual symptoms had resolved, unaided visual acuity had improved to approximately 6/4.5 bilaterally, and repeat ultrasonography confirmed complete resolution of the effusions. At approximately nine weeks, visual recovery was sustained, with near-plano autorefraction and no recurrent effusions. Daratumumab had subsequently been discontinued for unrelated haematological reasons. This case highlights ciliochoroidal effusion as a potential cause of acute myopic refractive change following daratumumab administration. Although the temporal association raises suspicion of drug-related ocular toxicity, causality cannot be established from a single case. Resolution during continued treatment illustrates a comparatively mild presentation but should not be interpreted as evidence that daratumumab can routinely be continued following ocular adverse events.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-18
DOI
https://doi.org/10.7759/cureus.119912
Primary Topic
Drug-Induced Ocular Toxicity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Bilateral Choroidal Effusions With Acute Myopic Shift After Daratumumab

Sheetal Shirke, Angus van der Nagel
Cureus
Drug-Induced Ocular Toxicity
article

Bilateral Choroidal Effusions With Acute Myopic Shift After Daratumumab

Sheetal Shirke, Angus van der Nagel
article en

Abstract

Daratumumab is a CD38-directed monoclonal antibody increasingly used in haematological malignancies. Infusion-related reactions are well recognised, but ocular adverse events are uncommon and may be under-recognised. We report a man in his 30s with relapsed T-cell lymphoblastic lymphoma/leukaemia following allogeneic stem cell transplantation who developed acute bilateral blurred vision within 24 hours of his first daratumumab infusion. The infusion was complicated by a hypersensitivity reaction requiring treatment with antihistamines and corticosteroids. Ophthalmic assessment demonstrated unaided visual acuity of 6/9 in the right eye and 6/15 in the left eye, bilateral myopic refractive changes, normal intraocular pressures, and deep, quiet anterior chambers. Optical coherence tomography was unremarkable, whilst B-scan ultrasonography demonstrated small bilateral superior choroidal effusions. Following discussion with the treating haematology team, the patient was managed conservatively with ophthalmic monitoring whilst daratumumab was continued. At two weeks, his visual symptoms had resolved, unaided visual acuity had improved to approximately 6/4.5 bilaterally, and repeat ultrasonography confirmed complete resolution of the effusions. At approximately nine weeks, visual recovery was sustained, with near-plano autorefraction and no recurrent effusions. Daratumumab had subsequently been discontinued for unrelated haematological reasons. This case highlights ciliochoroidal effusion as a potential cause of acute myopic refractive change following daratumumab administration. Although the temporal association raises suspicion of drug-related ocular toxicity, causality cannot be established from a single case. Resolution during continued treatment illustrates a comparatively mild presentation but should not be interpreted as evidence that daratumumab can routinely be continued following ocular adverse events.

Cureus
Townsville Hospital (AU)
Drug-Induced Ocular Toxicity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon